

Track record – Diseases – Oncology

Cost-effectiveness of everolimus for second-line treatment of metastatic renal cell carcinoma in Serbia. Mihajlović J, Pechlivanoglou P, Sabo A, Tomić Z, Postma MJ. Clin Ther. 2013 Dec;35(12):1909-22. doi: 10.1016/j.clinthera.2013.10.004. Epub 2013 Nov 13.

Treatment sequencing survival model for patients with multiple myeloma ineligible for stem cell transplantation (SCT). Heeg B, Van Agthoven M, van Beurden-Tan C, Liwing J, Mellqvist U, Plesner T, Logman F, Aschan J, Einsele H, Treur M, Barendse M, Richardson PG, Palumbo A, Nahi H, Sonneveld P. Value in health 2014

Comparison of mean overall survival (os) and radiographic progression free survival (rpfs) based on matching adjusted indirect comparison of abiraterone acetate and enzalutamide for the treatment of castration-resistant prostate cancer in chemotherapy naïve patients. Dearden L, Majer I, Heeg B, Liwing J, Sandstrom K, Diels J. Value in Health 2014

The proportional odds model is more efficient than the multinomial logistic model for network meta-analyses of ordered outcomes. Bouwmeester W, van Beurden-Tan C, Bennison C, Heeg B. Value in health 2014.

Cost-effectiveness of the prophylactic HPV vaccine: an application to the Netherlands taking non-cervical cancers and cross-protection into account. Luttjeboer J, Westra TA, Wilschut JC, Nijman HW, Daemen T, Postma MJ. Vaccine. 2013 Aug 20;31(37):3922-7. doi: 10.1016/j.vaccine.2013.06.044. Epub 2013 Jun 24.

Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands. Westra TA, Stirbu-Wagner I, Dorsman S, Tutuhaturunewa ED, de Vrij EL, Nijman HW, Daemen T, Wilschut JC, Postma MJ. BMC Infect Dis. 2013 Feb 7;13:75. doi: 10.1186/1471-2334-13-75.

Cancer incidence and mortality in Serbia 1999-2009. Mihajlović J, Pechlivanoglou P, Miladinov-Mikov M, Zivković S, Postma MJ. BMC Cancer. 2013 Jan 15;13:18. doi: 10.1186/1471-2407-13-18.

Optimal Treatment Sequencing In Multiple Myeloma: An Exploratory Modeling Approach. Heeg B, Van Agthoven M, Liwing J, Mellqvist U, Plesner T, Logman F, Aschan J, Einsele H, Treur M, Barendse M, Richardson PG, Palumbo A, Nahi H, Sonneveld P. in 53rd ASH Annual Meeting and Exposition. 2011.

Economic evaluation of zoledronic acid for the prevention of osteoporotic fractures in postmenopausal women with early-stage breast cancer receiving aromatase inhibitors in the UK. Logman JF, Heeg BM, Botteman MF, Kaura S, van Hout BA. Ann Oncol. 2010 Jul;21(7):1529-36. doi: 10.1093/annonc/mdp560. Epub 2009 Dec 2.

Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: adaptation of an existing cohort model to the situation in the Netherlands. Rogoza RM, Westra TA, Ferko N, Tamminga JJ, Drummond MF, Daemen T, Wilschut JC, Postma MJ. Vaccine. 2009 Jul 30;27(35):4776-83. doi: 10.1016/j.vaccine.2009.05.085. Epub 2009 Jun 17.

Economic evaluation of zoledronic acid for the prevention of osteoporotic fractures in postmenopausal women with early-stage breast cancer receiving aromatase inhibitors in the UK. Logman JF, Heeg B, Botteman MF, Kaura S, van Hout BA. Annals of Oncology 12/2009; 21(7):1529-36.

Long-acting methylphenidate-OROS in youths with attention-deficit hyperactivity disorder suboptimally controlled with immediate-release methylphenidate: a study of cost effectiveness in The Netherlands. Faber A, van Agthoven M, Kalverdijk LJ, Tobi H, de Jong-van den Berg LT, Annemans L, Postma MJ. CNS Drugs. 2008;22(2):157-70.

Cost considerations in the treatment of colorectal cancer. Jansman FG, Postma MJ, Brouwers JR. Pharmacoeconomics. 2007;25(7):537-62. Review.

Cost-effectiveness of zoledronic acid in the prevention of fractures in postmenopausal women with early breast cancer receiving aromatase inhibitor: Application to the United Kingdom. Logman F, Heeg B, Botteman M, Marfatia A, van Hout B. 1146. EJC Supplements 09/2007; 5(4):156-156.

Costs of chemotherapy in the treatment of colorectal cancer. Jansman FG, Postma MJ. Eur J Health Econ. 2006 Jun;7(2):145-6. No abstract available.

Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands. Jansman FG, Postma MJ, van Hartkamp D, Willemsse PH, Brouwers JR. Clin Ther. 2004 Apr;26(4):579-89.